Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.95 - $52.34
Previous CloseN/A
Volume126.35K
Average Volume (3M)1.83M
Market Cap
$4.44B
Enterprise Value$5.18B
Total Cash (Recent Filing)$98.59M
Total Debt (Recent Filing)$141.61M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Apr 30, 2025EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding158,964,770
10 Day Avg. Volume2,403,811
30 Day Avg. Volume1,829,267
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.42
Price to Cash Flow (P/CF)-11.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.46
Enterprise Value/Ebitda-14.46
Forecast
1Y Price Target
$55.47Price Target Upside93.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst raises the price target for IONS from $52 to $55, reflecting confidence in the company's growth prospects.
PartnershipIONS announced a license agreement with Ono for exclusive global development and commercialization rights to sapablursen, which will bring significant upfront payments and potential future milestones.
Product LaunchThe launch of Tryngolza for lowering triglycerides could be a significant value driver, with potential approval expanding its market to 2.3 million patients in the U.S.
Bears Say
Market AppreciationThe market is highly under-appreciating the opportunity in severe hypertriglyceridemia, with Tryngolza comprising a significant portion of the overall valuation.
Trial DelaysThe enrollment for the study was completed one year later than expected due to COVID.
---
Ownership Overview
0.74% Insiders
39.51% Mutual Funds
0.23% Other Institutional Investors
44.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $52.34 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $4.44B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Apr 30, 2025 which is in 15 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Feb 19, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$1.124 by $0.464.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.08.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 158,964,770 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.66 in its last earnings report, beating expectations of -$1.124. Following the earnings report the stock price went down -0.438%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
---
Ionis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$55.47 (93.41% Upside)
$55.47 (93.41% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 426.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $705.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.28%
12-Months-Change
Fundamentals
Return on Equity
-93.03%
Trailing 12-Months
Asset Growth
0.45%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biotechnology company based in the United States, specializing in the discovery and development of RNA-targeted therapeutics. The company is a leader in antisense technology, which is used to develop drugs that address significant unmet medical needs. Ionis's core products and services revolve around its proprietary antisense technology platform, which is used to treat a variety of diseases, including neurological disorders, rare diseases, and cardiovascular conditions.
---
IONS Company Deck
---
IONS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Ionis Pharmaceuticals' successful launch of Tringolza and strong financial performance, with plans for future product launches and positive market response for existing products like WAYLIVRA. However, challenges remain in patient identification and clinical outcomes, as well as a decline in R&D revenue. The positive developments and strategic plans outweigh the challenges, indicating a positive outlook.Read More>---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$55.47
▲(93.41% Upside)
Technical Analysis
Best Analysts Covering IONS
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+12.27%
reiterated a buy rating 2 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +12.27% per trade.
---